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Guy Rouleau1,2Abstract
The director of the Montreal Neurological Institute
(MNI), Guy Rouleau, discusses the recent
announcement that the MNI will be completely
committed to open science.You recently announced that the Montreal
Neurological Institute is about to become a fully
open data institute. What does this entail?
Treatments for the diseases of the brain and nervous
system are one of the most compelling unmet medical
needs of our time. At the MNI, we see the most complex
of neurological and neurosurgical cases. For many of
these patients, we have not been able to offer any new
treatments for decades. The technology available to us
today can enable the scientific community to share
information and speed up discoveries. Seeing these
patients and knowing the talented researchers we have,
it makes sense to share as much information as possible.
In establishing itself as the world’s first academic institu-
tion operating fully on the principles of Open Science, the
MNI is realizing a vision in which early-stage drug
research is open, borderless, and global; world-class insti-
tutions around the world share expertise and collaborate
on fundamental discoveries; and new treatments and even
cures for devastating neurological diseases are within this
generation’s reach, promising enormous human and
economic benefits for the healthcare system and economy.
To achieve these goals, Open Science at the MNI will
be driven along five key axes: Open Access, Open Data,
Open Intellectual Property (IP), Open Biobank, and
Open Commercialization. That is, publishing research
results without restriction; sharing experimental data
freely with institutions around the world; refraining from
pursuing patents on MNI-generated discoveries; freelyCorrespondence: guy.rouleau@mcgill.ca
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below), within the limits of supply and respecting patient
confidentiality; and developing business models to bring
open-source discoveries, including new medicines, to
the marketplace.What do you think the benefits will be of this step?
From its inception, The MNI’s singular mission has been
to deploy scientific research in the service of patients,
families, and society. We see Open Science as a means
to expand the impact of our research by sharing it with
a global community of like-minded scientists.
We hope that the benefits will include a better under-
standing of the mechanisms of neurological diseases,
new therapeutic targets, and ultimately new treatments
for our patients. We believe that increasing openness in
research and operating along principles of collaboration
will improve transparency, reliability, and the impact of
research to accelerate the pace of discoveries that could
help patients around the world who have devastating
neurological diseases and disorders. By allowing re-
searchers from around the world with many different
interests and expertise to access our data, research will
progress exponentially for the benefit of patients.
The MNI will also set a precedent for other research in-
stitutes in adopting the principles of Open Science, lead-
ing in the development of new policies and tools required
to drive a faster and more complete exchange of scientific
knowledge. The hope is that we can share our experience
with the wider scientific community and serve as a case
study and blueprint that other scientific institutions can
follow in adopting the principles of Open Science.
In the last two years, we have hired more than a dozen
new researchers and physicians; we are in the midst of a
great rejuvenation. We predict that our new Open
Science policy will increase—and already has increase-
d—our capacity to attract highly talented researchers
and trainees who are highly committed to and engaged
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from first discussing the idea to being ready to
commit to being open?
The MNI has a long history of Open Science, particu-
larly in brain imaging. We have one of the three largest
brain-imaging centers in the world. Researchers around
the globe use the Atlas of the Human Brain in Stereotaxic
Space (http://www.thehumanbrain.info/brain/index.php),
and our scientists have developed software and image-
analysis platforms that are open access and set a gold
standard.
Personally, as a physician and clinician-researcher, I
have always been convinced that Open Science is the
right thing to do ethically. On the basis of that personal
conviction, I have decided to persuade the rest of the
community to take this step. Around 18 months passed
between the first discussions of the idea to committing
to being open.
The faculty vote was passed unanimously, but
were there faculty members who were reluctant
and needed to be persuaded?
I would say that because of this tradition at MNI, none
of our faculty were reluctant, but some raised the very
relevant and important point of feasibility and ques-
tioned the potential additional work burden that this
new initiative would create on their own activities.
We worked on a buy-in process that started by defin-
ing an MNI-tailored Open Science approach and frame-
work and key elements to consider. We then mapped
existing open science activities versus closed activities at
the MNI. For over a year, we engaged in a consultation
process with MNI faculty, staff, and students, consisting of
seminars, polls, town hall meetings, and Q&A sessions.
An independent research group was commissioned to
perform a social science study using structured question-
naires to identify potential barriers and limitations related
to Open Science. Finally, we established Guiding
Principles with the agreement of all MNI members.
The institute is not pursuing IP. Universities often
see patents as a useful source of income: did you
receive any resistance from the finance
department at McGill over your stand on IP?
Since taking the very first steps towards our vision of
becoming an Open Science organization, we had very
strong and powerful support from McGill University’s
Principal, Suzanne Fortier, and many other senior mem-
bers of the University, confirming that our approach was
consistent with the university’s intellectual property
policy that allows researchers to decide whether to
publish or commercialize their research and inventions.
On the basis of the MNI experience with Open Science,
there is a clear potential to spread these principles andtheir benefits more broadly at the university level as well
as at a global level.
Furthermore, the kind of science that the MNI does is
so early-stage that we would rather provide data that
others could use to develop patentable medicines. It
comes back to what we aim for: accelerating science, not
making money.
Of course there is a risk that we might lose the eco-
nomic returns of a blockbuster drug or a new interven-
tion, but we are ethically committed to taking that risk,
as the bigger risk is for our patients who are waiting for
answers and new treatments.
As a neurological institute, openness requires
consent from the patients that you see. Has this
been a problem?
The objective of our Clinical, Biological, Imaging and
Genetic data Repository (C-BIGR) is to collect biological
material as well as clinical and imaging information from
patients and research participants in order to enable
cutting-edge research projects that will advance our
understanding of neurological diseases. Aggregating col-
lections of material and data from patients who have
neurological diseases, some of which are rare, will per-
mit investigations into the fundamental molecular alter-
ations underlying patient disease; permit discovery of
biomarkers to improve patient diagnosis; and permit
tissue-based translational research that will allow us to
develop new treatments that can alter the natural history
of these devastating diseases.
The C-BIGR will also empower patients by allowing
them to participate indirectly in research aimed at
advancing our understanding of their diseases.
Our patients perceive this initiative as extremely im-
portant and crucial and are highly supportive, not only
for themselves but mainly for the generations to come
that would benefit from the extraordinary outcomes of
such a culture and new way of doing research.
Over 90% of patients agree to participate.
What do you think are going to be the biggest
challenges of being completely open?
The first challenge is to be able to make meaningful data
accessible, not just raw data. The second challenge will
certainly be building the right infrastructure to support
our community in achieving this. A third challenge that
we foresee is the ability to deploy mechanisms to meas-
ure, increase the impact of, and fully acknowledge our
researchers’ and trainees’ contributions in the Open
Science context. A fourth and obvious challenge is the
shift of mindset implied by this new policy that will
allow people to work more collectively in a community,
both at an individual level for each researcher in their
own lab and at an institutional level.
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there levels of openness that currently can’t be
reached because of legal or technical problems?
We are currently working on deploying the full suite of
tools and platforms that constitute the support infrastruc-
ture for Open Science. Our Open Science policy and its
guiding principles are now integrated into all contract
agreements with our partners, both public and private.
On the legal side, issues regarding third parties’ existing
intellectual property rights on techniques or methods used
by our researchers in their labs—for instance, the existing
international legal battle on CRISPR technology—may
actually represent legal limitations or hurdles to the
confirmation of new partnerships with industry.Competing interests
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